Propanc Biopharma (PPCB) Registration filing summary

Company overview and business model

• Focuses on developing novel cancer treatments targeting pancreatic, ovarian, and colorectal cancers using a proprietary proenzyme therapy (PRP) designed to prevent recurrence and metastasis by targeting cancer stem cells.

• Lead product PRP is in preclinical development, with plans to initiate a Phase Ib first-in-human study in advanced solid tumor patients, subject to sufficient financing.

• Holds an extensive intellectual property portfolio with 85 granted or allowed patents and 5 applications in key jurisdictions covering PRP and related technologies.

• Operates primarily from Australia, with research collaborations in Europe, and aims to establish global markets for its technology.

Financial performance and metrics

• No revenue-generating operations to date; accumulated deficit of $121.6 million as of March 31, 2025.

• Net loss of $54.9 million for the nine months ended March 31, 2025, driven by $51.3 million in stock-based compensation and $1.5 million in R&D and consulting expenses.

• Cash balance of $50,760 and current liabilities of $4.3 million as of March 31, 2025; negative working capital and recurring operating losses raise substantial doubt about going concern.

• Relies on debt and equity financings, including convertible notes with variable conversion features and high dilution risk.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.6 million from the IPO (assuming $5.00 per share and no over-allotment), primarily allocated to working capital and general corporate purposes.

• Management retains broad discretion over the allocation of proceeds, with plans to fund operations for 12–18 months post-offering.